Immunopathogenesis of cutaneous T-cell lymphomas

Hematology/Oncology Clinics of North America

Volumn 17, Issue 6, 2003, Pages 1313-1317

  Bagot, Martine ^a   Boumsell, Laurence ^a   Bensussan, Armand ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD158K ANTIGEN; CD3 ANTIGEN; CELL RECEPTOR; DIPEPTIDYL PEPTIDASE IV; ILT2 RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; PROTEIN KIR3DL2; PROTEIN P140; RECEPTOR PROTEIN; SC5 RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PURIFICATION; CARCINOGENESIS; CUTANEOUS T CELL LYMPHOMA; FEEDBACK SYSTEM; GENE REARRANGEMENT; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE CLONE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SEZARY SYNDROME;

EID: 0345735913     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00116-3     Document Type: Review

References (22)

1. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997;90:354-71.
2. Bagot M, Echchakir H, Mami-Chouaib F, Delfau-Larue MH, Charue D, Bernheim A, et al. Isolation of tumor-specific cytotoxic CD4+ and CD4 + CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 1998;91:4331-41.
3. Echchakir H, Bagot M, Martinvallet D, Dorothée G, Legouvello S, Boumsell L, et al. Cutaneous T cell lymphoma-reactive CD4+ and CD4+ CD8dim+ CTL clones display T helper 1 cytokine profile and use a Fas/Fas ligand-independent mechanism for autologous tumor cell lysis. J Invest Dermatol 2000;115:74-80.
4. Edelman J, Meyerson HJ. Dimmished CD3 expression is useful for detecting and enumerating Sezary cells. Am J Clin Pathol 2000;114:467-77.
5. Laetsch B, Haffner AC, Dobbeling U, Seifert B, Ludwig E, Burg G, et al. CD4+/CD7 - T cell frequency and polymerase chain reaction-based clonality assay correlate with stage in cutaneous T cell lymphomas. J Invest Dermatol 2000;114:107-13.
6. Rappl G, Muche JM, Abken H, Sterry W, Tilgen W, Ugurel S, et al. CD4 + CD7 - T cells compose the dominant T-cell clone in the peripheral blood of patients with Sezary syndrome. J Am Acad Dermatol 2001;44:456-61.
7. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001;115:885-92.
8. Bernengo MG, Novelli M, Quaglino P, Lisa F, De Matteis A, Savoia P, et al. The relevance of the CD4+ CD26 - subset in the identification of circulating Sezary cells. Br J Dermatol 2001;144:125-35.
9. Dereure O, Portales P, Clot J, Guilhou JJ. Decreased expression of Fas (APO-1/ CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas. Br J Dermatol 2000;143:1205-10.
10. Zoi-Toli O, Vermeer MH, De Vries E, Van Beek P, Meijer CJ, Willemze R. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 2000;143:313-9.
11. Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46:95-106.
12. Poszepczynska E, Bagot M, Echchakir H, Martinvalet D, Ramez M, Charue D, et al. Functional characterization of an IL-7-dependent CD4 + CD8alphaalpha+ Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. Blood 2000;96:1056-63.
13. Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, di Donato C, et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med 1996;184:505-18.
14. Moretta A, Biassoni R, Bottino C, Pende D, Vitale M, Poggi A, et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997;155:105-17.
15. Bagot M, Moretta A, Sivori S, Biassoni R, Cantoni C, Bottino C, et al. CD4 (+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood 2001;97:1388-91.
16. Wechsler J, Bagot M, Nikolova M, Moretta A, Martin-Garcia N, Boumsell L, et al. Killer cell immunoglobulin-like receptor expression delineates in situ Sezary syndrome lymphocytes. J Pathol 2003;199:77-83.
17. Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D, et al. Allelic polymorphism synergizes with varable gene content to individualize human KIR genotype. J Immunol 2002;168:2307-15.
18. Musette P, Michel L, Jean-Louis F, Bagot M, Bensussan A. Polymorphic expression of CD158k/ p140/KIR3DL2 in Sezary patients. Blood 2003;101:1203.
19. Navarro F, Llano M, Bellon T, Colonna M, Geraghty DE, Lopez-Botet M. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 1999;29:277-83.
20. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 1999;11:603-13.
21. Nikolova M, Musette P, Bagot M, Boumsell L, Bensussan A. Engagement of ILT2/CD85j in Sezary syndrome cells inhibits their CD3/TCR signaling. Blood 2002;100:1019-25.
22. Nikolova M, Tawab A, Marie-Cardine A, Bagot M, Boumsell L, Bensussan A. Increased expression of a novel early activation surface membrane receptor in cutaneous T cell lymphoma cells. J Invest Dermatol 2001;116:731-8.